ClinicalTrials.gg
Not yet recruitingNCT07172672Updated Sep 26, 2025

The TiMeD-T1D Project

An interventional study of 400 mL Fresubin Energy Drink and 100 mL heavy cream with the addition of the 18F-FTHA radiotracer in Postprandial Lipid Metabolism and Type 1 Diabetes (T1D), sponsored by University of Aarhus. Not yet recruiting at 1 site in Denmark. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-26.

Sponsored by University of Aarhus · Not applicable, Interventional, and Basic science

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 24 studies in Diabetes Mellitus, Type 1 by University of Aarhus — 6 open to participants now, 6 under way, none of them phase 3. Diabetes Mellitus, Type 1 · University of Aarhus.

Planned enrollment
17th of 21
10 · median 20
Started
2025
with 2 others
No phase
18 of 24
5 open now
Registered
21st of 24
by date

Among the 24 studies in Diabetes Mellitus, Type 1 by University of Aarhus, this one is the 17th largest by planned enrollment of the 21 interventional ones that give a count, is one of 3 that started in 2025, is one of 18 with no phase, and was the 21st registered.

Diabetes Mellitus, Type 1

3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

6 of the 24 studies in Diabetes Mellitus, Type 1 by University of Aarhus are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Diabetes Mellitus, Type 1 by University of Aarhus, or all of them as a file.
02

Study summary

The aim of the proposed study is to investigate the metabolic consequences of varying the timing of meal insulin boluses and skipping boluses altogether in individuals with type 1 diabetes.

The investigator hypothesize that delaying or skipping meal insulin boluses leads to greater ectopic fat storage due to a delayed stimulation of lipoprotein activity and delayed suppression of lipolysis and VLDL-TG secretion.

Read the detailed description

The study will be carried out as a randomized cross-over clinical investigational trial. The investigators will include 10 individuals with type 1 diabetes. The subjects will be invited for four visits in total: one screening visit and three test days separated by a one-week washout period. At the test days, subjects will consume a liquid mixed meal and: 1) take a meal bolus of insulin 20 min before consuming a liquid mixed meal or 2) take a meal bolus of insulin 20 min after the meal or 3) skip the meal bolus of insulin.

The investigators will apply the 18F-FTHA meal fat tracer method to the liquid mixed meal to determine whole-body organ-specific meal fat storage.

The volunteers will arrive fasted (8 hours) at the Department of Nuclear Medicine \& PET-Centre at 9.00 a.m. Upon arrival, participants will be placed in a bed and have an arterial catheter placed for arterial blood sampling collected at baseline and during the entire trial day. Approximately one hour after arriving, participants will consume a liquid mixed meal consisting of 400 mL Fresubin Energy Drink and 100 mL heavy cream with the addition of the 18F-FTHA radiotracer. 5 hours after consumption of the liquid mixed meal one static whole-body PET-scan will be performed with a duration of 1 hours. After the PET-scan participants will be provided with a meal. Subsequently, the investigator will make sure the participants is metabolic corrected and then the trial day is ended, and they can go home.

The three test days will be conducted in the same way, except for the timing of insulin bolus administration relative to the meal, which will vary as follows:

  1. Meal insulin bolus 20 min before consumption of a liquid mixed meal (as recommended)
  2. Meal insulin bolus 20 min after consumption of a liquid mixed meal
  3. Skipping the insulin bolus Insulin will be administered subcutaneously, with the dose determined based on the composition of the liquid mixed meal.

To correct for attenuation, the investigators will perform one ultra-low dose, non-contrast enhanced CT scan on each study day.

Results will be presented as means ± SD when possible. Primary and secondary outcomes will be analyzed using a two-way mixed model of linear regression with repeated measurements together with standard statistical methodology to compare results between study days. P-values \< 0.05 will be considered statistically significant. Statistical analyses will be carried out using R and visualization with GraphPad Prism.

The investigators base the sample size on our primary endpoint visceral meal fat uptake. Based on a previous (unpublished) study from our group with a test / re-test design using18F-FTHA PET together with a mixed meal, we can estimate a sample size based on the repeatability coefficient (RCP) of 45% in visceral adipose tissue. With a significance level of 0.05 and power of 80% and, the investigators will need 10 individuals to detect a 15% difference in meal fat uptake in adipose tissue. In the event of participant dropout, additional individuals will be recruited to ensure the intended sample size is maintained.

03

Conditions studied

  • Postprandial Lipid Metabolism
  • Type 1 Diabetes (T1D)

Keywords

  • FTHA PET
  • Insulin
  • Postprandial metabolism
  • Human
  • Meal fat storage in skeletal muscle, liver, brain, and subcutaneous fat adipose tissue
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Type 1 diabetes duration > 3 years or c-peptide negative
  • Written and

Exclusion criteria

Exclusion Criteria:

  • Medicine with an impact on blood glucose or blood pressure
  • Affected screening blood sample as evaluated by the clinical responsible investigator.
  • Alcohol or substance abuse
  • > 35 kg/m2 or \< 18.5 kg/m2
  • Participation in other clinical trials involving ionized radiation within the last 6 months
  • Lactose intolerance
  • Doesn't speak and understand Danish.
  • Severe claustrophobia.
  • Commitment to special diets
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Meal insulin bolus 20 min before consumption of a liquid mixed meal

    Dietary Supplement: 400 mL Fresubin Energy Drink and 100 mL heavy cream with the addition of the 18F-FTHA radiotracer

  • Experimental
    Meal insulin bolus 20 min after consumption of a liquid mixed meal

    Dietary Supplement: 400 mL Fresubin Energy Drink and 100 mL heavy cream with the addition of the 18F-FTHA radiotracer

  • Experimental
    Skipping the insulin bolus

    Dietary Supplement: 400 mL Fresubin Energy Drink and 100 mL heavy cream with the addition of the 18F-FTHA radiotracer

Interventions

  • Dietary supplement400 mL Fresubin Energy Drink and 100 mL heavy cream with the addition of the 18F-FTHA radiotracer

    400 mL Fresubin Energy Drink and 100 mL heavy cream with the addition of the 18F-FTHA radiotracer

06

What researchers measure

Primary outcomes

  1. Difference in meal fat storage in visceral adipose tissue

    Difference in meal fat storage (18F-FTHA PET scan) in visceral adipose tissue following a liquid mixed meal and varying the timing or skipping of meal insulin boluses.

    Time frame: 18F-FTHA PET scan 300 minutes after consumption of the liquid mixed meal

Secondary outcomes

  1. Difference in postprandial triglycerides

    Postprandial triglycerides measured as area under the curve ( iAUC of plasma triglyceride concentration).

    Time frame: -20 to 360 minutes after consumption of the mixed meal

  2. Meal fat storage in target organs and tissues

    Differences in meal fat storage in skeletal muscle, liver, brain, and subcutaneous fat adipose tissue (18F-FTHA PET scan) following a mixed meal, comparing different timings of insulin administration.

    Time frame: 300 min after consumption of the mixed meal

  3. Postprandial hormonal response and metabolites

    Plasma concentrations of free fatty acids, insulin, glucagon, blood glucose, and potentially others following a liquid test meal, comparing different timings of insulin administration.

    Time frame: -20 to 360 minutes after consumption of the mixed meal

07

Study locations

1 site
  • Department of Nuclear Medicine & PET-Centre, AUH Palle Juul-Jensens Blvd. 165, 8200 Aarhus N, Denmark and Medical Research Laboratories/Steno Diabetes Center Aarhus, AUH Palle Juul-Jensens Blvd. 11, 8200 Aarhus N, Denmark
    Aarhus, 8200, Denmark
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2025; primary completion for Feb 2027, 15 months later.

Of 852 non-industry interventional studies with no phase under Diabetes Mellitus, Type 1, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 37. This study's planned 15 months is below that.

Counting every sponsor, half of 957 studies reached it within 18 months; a quarter within 9 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 8, 2025
First posted
Sep 15, 2025
StartEst.
Nov 1, 2025
Primary completionEst.
Feb 1, 2027
CompletionEst.
Nov 1, 2027
Last update
Sep 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07172672
Responsible party
Sponsor
First posted
Sep 15, 2025
Start date
Nov 1, 2025 (estimated)
Primary completion
Feb 1, 2027 (estimated)
Completion
Nov 1, 2027 (estimated)
Last update
Sep 26, 2025

Study contacts

Jens H. Voigt, MD
Contact
Jens.voigt@clin.au.dk
0026395294
Esben Søndergaaard, MD, PhD
Contact
Esben.sondergaard@clin.au.dk
004528730943
Esben Søndergaard, MD, PhD
study director · Steno Diabetes Center Aarhus, Aarhus University Hospital, 8200 Aarhus, Denmark

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion